These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 17333449

  • 21. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
    Pongchaiyakul C, Nanagara R, Songpatanasilp T, Unnanuntana A.
    J Med Econ; 2020 Jul; 23(7):776-785. PubMed ID: 32063082
    [Abstract] [Full Text] [Related]

  • 22. Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.
    Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA.
    Osteoporos Int; 2014 Jan; 25(1):325-37. PubMed ID: 24114398
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.
    Svedbom A, Hadji P, Hernlund E, Thoren R, McCloskey E, Stad R, Stollenwerk B.
    Osteoporos Int; 2019 Sep; 30(9):1745-1754. PubMed ID: 31270592
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
    Goeree R, Blackhouse G, Adachi J.
    Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
    [Abstract] [Full Text] [Related]

  • 25. Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision.
    Alzahouri K, Bahrami S, Durand-Zaleski I, Guillemin F, Roux C.
    Joint Bone Spine; 2013 Jan; 80(1):64-9. PubMed ID: 22366150
    [Abstract] [Full Text] [Related]

  • 26. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
    Tosteson AN, Burge RT, Marshall DA, Lindsay R.
    Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
    [Abstract] [Full Text] [Related]

  • 27. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
    Ström O, Jönsson B, Kanis JA.
    Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
    [Abstract] [Full Text] [Related]

  • 28. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
    Yoshimura M, Moriwaki K, Noto S, Takiguchi T.
    Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
    [Abstract] [Full Text] [Related]

  • 29. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.
    Borgström F, Johnell O, Jönsson B, Zethraeus N, Sen SS.
    Bone; 2004 Jun; 34(6):1064-71. PubMed ID: 15193554
    [Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.
    Schousboe JT, Nyman JA, Kane RL, Ensrud KE.
    Ann Intern Med; 2005 May 03; 142(9):734-41. PubMed ID: 15867405
    [Abstract] [Full Text] [Related]

  • 31. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
    Berto P, Maggi S, Noale M, Lopatriello S.
    Aging Clin Exp Res; 2010 Apr 03; 22(2):179-88. PubMed ID: 20145427
    [Abstract] [Full Text] [Related]

  • 32. Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women.
    Lundkvist J, Johnell O, Cooper C, Sykes D.
    Osteoporos Int; 2006 Feb 03; 17(2):201-11. PubMed ID: 16027955
    [Abstract] [Full Text] [Related]

  • 33. [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].
    Jönsson L, Borgström F, Zethraeus N.
    Ugeskr Laeger; 2003 Oct 20; 165(43):4112-6. PubMed ID: 14619061
    [No Abstract] [Full Text] [Related]

  • 34. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D.
    Arthritis Rheum; 1999 Jun 20; 42(6):1246-54. PubMed ID: 10366118
    [Abstract] [Full Text] [Related]

  • 35. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women.
    Christensen PM, Brixen K, Gyrd-Hansen D, Kristiansen IS.
    Basic Clin Pharmacol Toxicol; 2005 May 20; 96(5):387-96. PubMed ID: 15853932
    [Abstract] [Full Text] [Related]

  • 36. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
    Grima DT, Papaioannou A, Thompson MF, Pasquale MK, Adachi JD.
    Osteoporos Int; 2008 May 20; 19(5):687-97. PubMed ID: 18008100
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
    Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA.
    Osteoporos Int; 2011 Mar 20; 22(3):967-82. PubMed ID: 20936401
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
    Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, Melton LJ, Bauer DC, Ensrud KE.
    JAMA; 2007 Aug 08; 298(6):629-37. PubMed ID: 17684185
    [Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
    Le QA, Hay JW, Becker R, Wang Y.
    Ann Pharmacother; 2019 Feb 08; 53(2):134-143. PubMed ID: 30160186
    [Abstract] [Full Text] [Related]

  • 40. Comparison of plain vertebral X-ray and dual-energy X-ray absorptiometry for the identification of older women for fracture prevention in primary care.
    Robinson PJ, Bell RJ, Lanzafame A, Segal L, Kirby C, Piterman L, Davis SR.
    Intern Med J; 2013 Jan 08; 43(1):38-45. PubMed ID: 22931254
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.